



Certificate of Mailing:

The undersigned certifies that this correspondence is being sent via first-class mail, with adequate postage, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, this 14th day of May 2007.


Linda S. Evans



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Karlsson et al.

Atty. Docket: PRD2127US-PCT

Serial No.: 10/572,985

Examiner: unknown

International

Group Art Unit: unknown

Filing Date: 24 September 2004

Confirmation No.: 9021

For: Analyzing Histamine H4 Receptor-Mediated Effects in Whole Blood

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE LISTING REQUIREMENTS

Sir:

This is a response to the Notification To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures dated February 13, 2007 (copy enclosed). A petition with the fee for a one-month extension of time accompanies this response. If any other fees are necessary for the filing of this response (including for any extension of time), please charge all required fees to Deposit Account No. 10-0750.


In response to the Notice and in accordance with 37 C.F.R. § 1.821(e), enclosed in connection with the above-referenced U.S. national-phase application of International Application No. PCT/US2004/031614 is a diskette containing a computer readable form (CRF) of the paper copy of the Sequence Listing included in the international application as published as WO 2005/031308. The information recorded in the enclosed CRF is

identical to the written sequence listing of the original paper copy and thus includes no new matter.

In view of the foregoing, the requirements of 37 C.F.R. §§ 1.821 - 1.825 have been met. Accordingly, Applicant requests prompt examination on the merits.


Respectfully submitted,

Date: May 14, 2007



Linda S. Evans
Reg. No. 33,873

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933-7003
(858) 320-3406



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/572,985	Lars Karlsson	PRD2127US

27777
 PHILIP S. JOHNSON
 JOHNSON & JOHNSON
 ONE JOHNSON & JOHNSON PLAZA
 NEW BRUNSWICK, NJ 08933-7003

RECEIVED

FEB 16 2007

J&J PAT. DKT. SECTION

INTERNATIONAL APPLICATION NO.	
PCT/US04/31614	
I.A. FILING DATE	PRIORITY DATE
09/24/2004	09/26/2003

CONFIRMATION NO. 9021

371 FORMALITIES LETTER

OC000000022464831

Date Mailed: 02/13/2007

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://portal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or

visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

PATRICIA A BOOKER

Telephone: (703) 308-9140 EXT 204

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/572,985	PCT/US04/31614	PRD2127US

FORM PCT/DO/EO/922 (371 Formalities Notice)